Steris raises FY26 adjusted EPS view to $10.15-$10.30 from $9.90-$10.15

Consensus $10.09. Backs FY25 revenue view up 8%-9%. The company said, “For fiscal 2026, the Company expects as reported revenue from continuing operations to increase 8-9%, unchanged from prior outlook. Expectations for foreign currency impact are reduced to 100 basis points from prior expectations of 200 basis points. Constant currency organic revenue from continuing operations is now anticipated to grow 7-8% compared with prior expectations of 6-7%. Adjusted earnings per diluted share from continuing operations are also increasing and are now expected to be in the range of $10.15 to $10.30 compared with prior expectations of $9.90 to $10.15. Included in this outlook is the negative impact of tariffs, estimated to reduce pre-tax profit by approximately $45 million, unchanged from prior outlook. The fiscal 2026 outlook assumes an effective tax rate of approximately 24%, an increase of 50 bps from our prior expectation of approximately 23.5%. Capital expenditures are anticipated to be approximately $375 million, unchanged from prior expectations. Free cash flow is now expected to be approximately $850 million, an increase from prior expectations of $820 million.”